QIAGEN Expands Supervisory Board With Appointment of a New Member

$QGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $QGEN alert in real time by email

VENLO, Netherlands--()--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.

Mr. Ebeling joins QIAGEN as part of a process launched by the Supervisory Board in 2020 to further complement and enhance the Board’s already extensive experience in Life Sciences and diagnostics. The addition of Mr. Ebeling brings the number of current Supervisory Board members to eight.

“On behalf of the Supervisory Board and Managing Board, I would like to welcome Thomas Ebeling to QIAGEN. This appointment further deepens our expertise and experience in many ways, in particular given his international background in healthcare and extensive experience in general management,” said Lawrence Rosen, Chairman of the Supervisory Board. “As we continue the review process initiated in 2020, the Supervisory Board continues to pursue the highest level of excellence in corporate governance and support of the management team to create value for QIAGEN’s stakeholders, including its shareholders.”

Mr. Ebeling has been an advisor in recent years to various businesses after having served as the CEO of the publicly-listed German media group ProSiebenSat.1 Media from 2009 to 2018. Prior to that, he worked for the global healthcare company Novartis from 1997 to 2008, including roles as CEO of Novartis Pharmaceuticals and also as CEO of Novartis Consumer Health. He began his career in 1987 and held various positions in marketing and sales in the consumer goods industry before joining Novartis. Mr. Ebeling, who has a degree in psychology from the University of Hamburg, has previously served on the Supervisory Boards of Bayer AG and Lonza AG.

Please find the full press release here.

Get the next $QGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$QGEN

DatePrice TargetRatingAnalyst
2/19/2025$52.00 → $42.00Outperform → Neutral
Robert W. Baird
1/6/2025$48.00Overweight → Equal-Weight
Morgan Stanley
12/10/2024$42.50 → $54.00Hold → Buy
Jefferies
10/17/2024$49.00Buy → Hold
HSBC Securities
6/27/2024$50.00Peer Perform → Outperform
Wolfe Research
12/19/2023$44.00Equal Weight
Wells Fargo
12/13/2023Peer Perform
Wolfe Research
12/7/2023$50.00Neutral → Buy
Goldman
More analyst ratings

$QGEN
Press Releases

Fastest customizable press release news feed in the world

See more
  • QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

    New QIAstat-Dx Gastrointestinal Panel 2 Mini B adds to QIAGEN's growing U.S. menu for syndromic testing of gastrointestinal infections Panel delivers rapid detection of five common bacterial pathogens for outpatient use, aiding fast and informed treatment decisions QIAGEN building momentum in the U.S. syndromic testing market with six regulatory clearance of panels for use on QIAstat-Dx within the last 10 months QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

    QIAGEN files lawsuit against bioMérieux with German Unified Patent Court to protect key innovations in its QuantiFERON technology QuantiFERON-TB Gold Plus plays a critical role in fighting the spread of TB worldwide QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which i

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

    New facility reflects QIAGEN's commitment to enhancing its bioinformatics data center infrastructure in the Australia, New Zealand, New Guinea and surrounding islands region New data center in Melbourne meets Australian regulations to ensure quality, scalable and trustworthy support for Omics analysis and interpretation in genomic testing labs Expands a QIAGEN network of seven data centers around the globe designed to ensure highest level of data security, compliance and operational excellence worldwide   QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinf

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$QGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$QGEN
SEC Filings

See more

$QGEN
Leadership Updates

Live Leadership Updates

See more
  • Neogen Announces the Appointment of New Board Member

    LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

    $NEOG
    $QGEN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

    BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.   Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer

    $QGEN
    $TPST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Quotient Limited Announces Appointment of Chief Commercial Officer

    JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil

    $QGEN
    $QTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

$QGEN
Financials

Live finance-specific insights

See more
  • QIAGEN delivers solid Q4 2024 growth ahead of outlook

    Q4 2024: Net sales of $521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of $0.39 and adjusted diluted EPS of $0.61 Net sales of $525 million CER ahead of outlook for at least $520 million CER and adjusted diluted EPS of $0.61 CER ahead of outlook for at least $0.60 CER QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace 30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023 FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7% Free cash flow rises 63% to $506 million 2025 outlook for about 4% CER sales grow

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 4027 GER: +49 (0)69 6610 2480 Conference ID: 9237018 To avoid waiting time, please join the event confer

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

    Venlo, the Netherlands, Nov. 06, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced results for the third quarter and first nine months of 2024. Net sales rose 5% to $502 million in Q3 2024 over Q3 2023, while results at constant exchanges rates (CER) of $502 million rose 6% and were above the outlook for at least $495 million CER. The adjusted operating income margin rose three percentage points to 29.6% on benefits from the recent decision to discontinue the NeuMoDx system as well as broader efficiency gains that have improved profitability and freed up resources for targeted reinvestment. Adjusted diluted earnings per share (EPS) were $0

    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$QGEN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more